<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04072276</url>
  </required_header>
  <id_info>
    <org_study_id>FU-EV-21e</org_study_id>
    <nct_id>NCT04072276</nct_id>
  </id_info>
  <brief_title>Long-Term Immunogenicity Study of Inactivated EV71 Vaccine in Children</brief_title>
  <official_title>Long-Term Immunogenicity Study of Inactivated EV71 Vaccine Produced in Vero Cells With Adjuvant AlPO4 in Children: Extension Study of Protocol CT-EV-21</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medigen Vaccine Biologics Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medigen Vaccine Biologics Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the long-term antibody titers of EV71 vaccine 4 and 5
      years after first dose vaccination for subjects at the age of 2 to &lt; 6 years , and 3 to 5
      years after first dose vaccination for subjects at the age of 2 months to &lt; 2 years
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an extension study of protocol CT-EV-21, to evaluate the long-term immunogenicity of
      EV71vaccine.

      The first study visit will be approximately 3 or 4 years after the administration of first
      vaccination of EV71 vaccine or placebo in CT-EV-21 study; 4 years after the first vaccination
      for subjects 2 to &lt; 6 years of age (2b), and 3 years after first dose for subjects 2 months
      to &lt; 2 years of age (2c and 2d).

      Subjects of 2b will remain in the study for approximately 12 months and will have 2 clinic
      visits; subjects of 2c and 2d will remain in the study for approximately 24 months and will
      have 3 clinic visits. Immunogenicity response against EV71 virus antigen at each visit will
      be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 15, 2019</start_date>
  <completion_date type="Anticipated">August 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum neutralizing antibody titer</measure>
    <time_frame>Up to 5 years after first dose of EV71 vaccination</time_frame>
    <description>Geometric mean titer (GMT) of EV71 neutralizing antibody titers at 4 and 5 years after first dose of EV71 vaccination for subjects of 2b; and 3 to 5 years after first dose of EV71 vaccination for subjects of 2c and 2d.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">312</enrollment>
  <condition>Enterovirus 71 Human</condition>
  <arm_group>
    <arm_group_label>EV71 Vaccine with Adjuvant AlPO4</arm_group_label>
    <description>EV71 Vaccine Produced in Vero Cells with Adjuvant AlPO4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant AlPO4</arm_group_label>
    <description>Placebo (Adjuvant AlPO4 only)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EV71 vaccine</intervention_name>
    <description>EV71 vaccine with Adjuvant AlPO4 and the placebo (Adjuvant AlPO4 only) were randomly administrated to subject in CT-EV-21 study</description>
    <arm_group_label>Adjuvant AlPO4</arm_group_label>
    <arm_group_label>EV71 Vaccine with Adjuvant AlPO4</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who have completed participation in study CT-EV-21
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have completed participation in study CT-EV-21 part 2b, 2c, and 2d, and
             have received protocol specified doses of EV71 vaccine or Placebo (total of 2 doses in
             part 2b, and 3 doses for part 2c and 2d).

          -  The subjects' guardians are able to understand and sign the informed consent form.

        Exclusion Criteria:

          -  Subjects and/or guardians who refuse to comply with the study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Min Huang, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheng-Hsun Chiu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gang Memorial Hospital, LinKou</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chien-Yu Lin, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mackay Memorial Hospital, HsinChu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nan-Chang Chiu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mackay Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mackay Memorial Hospital, HsincChu</name>
      <address>
        <city>Hsinchu</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital, Taipei</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hosptial</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, LinKou</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EV71 Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enterovirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

